These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1127 related articles for article (PubMed ID: 25765966)
1. Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad ®) administered concomitantly with a booster dose of a hexavalent vaccine in 12-23-month-old infants. Deichmann KA; Ferrera G; Tran C; Thomas S; Eymin C; Baudin M Vaccine; 2015 May; 33(20):2379-86. PubMed ID: 25765966 [TBL] [Abstract][Full Text] [Related]
2. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Madhi SA; Koen A; Cutland C; Groome M; Santos-Lima E Pediatr Infect Dis J; 2013 Aug; 32(8):889-97. PubMed ID: 23538523 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. Shinefield H; Black S; Thear M; Coury D; Reisinger K; Rothstein E; Xu J; Hartzel J; Evans B; Digilio L; Schödel F; Brown ML; Kuter B; Pediatr Infect Dis J; 2006 Apr; 25(4):287-92. PubMed ID: 16567978 [TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine. Halperin SA; Tapiéro B; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee A; Li M; Tomovici A Pediatr Infect Dis J; 2014 Jan; 33(1):73-80. PubMed ID: 24346596 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. Zepp F; Behre U; Kindler K; Laakmann KH; Pankow-Culot H; Mannhardt-Laakmann W; Beckers F; Descamps D; Willems P Eur J Pediatr; 2007 Aug; 166(8):857-64. PubMed ID: 17541639 [TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months. Vesikari T; Karvonen A; Lindblad N; Korhonen T; Lommel P; Willems P; Dieussaert I; Schuerman L Pediatr Infect Dis J; 2010 Jun; 29(6):e47-56. PubMed ID: 20508478 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa. Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine. Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981 [TBL] [Abstract][Full Text] [Related]
9. Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa®) and MMRV (ProQuad®) at 18 months of age. Kiely M; Billard MN; Toth E; Zafack JG; Landry M; Skowronski DM; De Serres G Vaccine; 2018 Oct; 36(45):6688-6694. PubMed ID: 30269915 [TBL] [Abstract][Full Text] [Related]
10. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib). Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R; Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305 [TBL] [Abstract][Full Text] [Related]
12. A randomized study to evaluate the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, haemophilus influenzae b, and meningococcal serogroup C combination vaccine administered to infants at 2, 4 and 12 months of age. Thollot F; Scheifele D; Pankow-Culot H; Cheuvart B; Leyssen M; Ulianov L; Miller JM Pediatr Infect Dis J; 2014 Dec; 33(12):1246-54. PubMed ID: 25037033 [TBL] [Abstract][Full Text] [Related]
13. Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants. Vesikari T; Borrow R; Da Costa X; Richard P; Eymin C; Boisnard F; Lockhart S Vaccine; 2017 Jan; 35(3):452-458. PubMed ID: 27939054 [TBL] [Abstract][Full Text] [Related]
14. Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. Omeñaca F; Vázquez L; Garcia-Corbeira P; Mesaros N; Hanssens L; Dolhain J; Gómez IP; Liese J; Knuf M Vaccine; 2018 Feb; 36(7):986-996. PubMed ID: 29336924 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087 [TBL] [Abstract][Full Text] [Related]
16. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants. Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12-18 months. Usonis V; Meriste S; Bakasenas V; Lutsar I; Collard F; Stoffel M; Tornieporth N Vaccine; 2005 Apr; 23(20):2602-6. PubMed ID: 15780442 [TBL] [Abstract][Full Text] [Related]
18. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children. Klein NP; Weston WM; Kuriyakose S; Kolhe D; Howe B; Friedland LR; Van Der Meeren O Vaccine; 2012 Jan; 30(3):668-74. PubMed ID: 22064267 [TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a hexavalent vaccine administered at 2, 4 and 6 months of age with or without a heptavalent pneumococcal conjugate vaccine: a randomized, open-label study. Tapiéro B; Halperin SA; Dionne M; Meekison W; Diaz-Mitoma F; Zickler P; Rubin E; Embree J; Bhuyan P; Lee AW; Li M; Tomovici A Pediatr Infect Dis J; 2013 Jan; 32(1):54-61. PubMed ID: 23241989 [TBL] [Abstract][Full Text] [Related]
20. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Ciarlet M; He S; Lai S; Petrecz M; Yuan G; Liu GF; Mikviman E; Heaton PM; Panzer F; Rose T; Koller DY; Van Damme P; Schödel F Pediatr Infect Dis J; 2009 Mar; 28(3):177-81. PubMed ID: 19209092 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]